{"success":true,"data":{"pressRelease":{"id":"76460","rtpr_id":"nGNX7RPDb3","ticker":"ALLR","exchange":"NASDAQ","all_tickers":["ALLR"],"title":"Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic","author":"Globe Newswire","published_at":"2026-06-30T12:00:00.577Z","article_body":"* Key U.S. patent now protects exclusivity for developing stenoparib with the\nstenoparib-DRP(®) until April 2042\nTARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc.\n(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage\npharmaceutical company dedicated to developing stenoparib (2X-121)—a\ndifferentiated, dual PARP and WNT pathway inhibitor—today announced that the\nUnited States Patent and Trademark Office (USPTO) has granted the key U.S.\npatent covering its proprietary stenoparib-specific Drug Response Predictor\n(DRP®) companion diagnostic. The newly granted patent has a term extending\ninto April 2042. The patent grant follows the USPTO’s Notice of Allowance\nfor the stenoparib DRP® companion diagnostic formerly announced by Allarity\nin April 2026.\n\n“This is a critical step for Allarity. With this U.S. patent now granted and\nproviding protection into 2042, we have established an important long-term\nintellectual property foundation for stenoparib and our DRP® companion\ndiagnostic,” said Thomas Jensen, Chief Executive Officer of Allarity\nTherapeutics. “Looking ahead, our goal is to use the stenoparib DRP® to\nhelp identify the patients most likely to benefit from treatment. This patent\nprovides the foundation for advancing a more precise, patient-selection-driven\napproach to ovarian cancer and accelerating stenoparib toward FDA approval.”\n\nThe granted patent covers methods for predicting clinical benefit from\nstenoparib based on gene-expression profiles derived from tumor samples, as\nwell as methods for selecting patients most likely to benefit from stenoparib\ntreatment using the stenoparib DRP® test. The patent protects Allarity’s\nlong-term commercial strategy, allowing exclusivity for stenoparib when used\nin concert with the stenoparib DRP® companion diagnostic in the United States\ninto April 2042.\n\nAllarity has also secured patent protection for the stenoparib DRP® in Europe\nand Australia into 2039, with related applications pending in several\nadditional international markets.\n\nAbout Stenoparib/2X-121\nStenoparib is an orally available, small-molecule dual-targeted inhibitor of\nPARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant\nattention as emerging therapeutic targets for cancer, principally due to their\nrole in regulating the WNT signaling pathway. Aberrant WNT/β-catenin\nsignaling has been implicated in the development and progression of numerous\ncancers, especially drug-resistant cancers. By inhibiting PARP and blocking\nWNT pathway activation, stenoparib’s unique therapeutic action shows\npotential as a promising therapeutic for many cancer types, including ovarian\ncancer, small cell lung cancer and colorectal cancer. Allarity has secured\nexclusive global rights for the development and commercialization of\nstenoparib, which was originally developed by Eisai Co. Ltd. and was formerly\nknown under the names E7449 and 2X-121. Allarity has completed its first Phase\n2 trial for stenoparib in advanced ovarian cancer patients. That trial showed\npromising and durable clinical benefit in ovarian cancer patients who had 2+\nlines of therapy and were given stenoparib twice daily. The updated data from\nthis study were presented at the AACR special conference on advances in\novarian cancer in September 2025. Note that analyses may change as the study\nfully matures. A new protocol was designed expressly to capitalize on this\nemerging clinical experience with stenoparib in platinum resistant patients\nand began enrolling patients in the summer of 2025. This amended protocol\nenrolls only platinum resistant or platinum-ineligible patients and is\ndesigned to accelerate the clinical development of stenoparib toward FDA\napproval. In parallel, a separate Phase 2 trial evaluating stenoparib in\ncombination with temozolomide for relapsed small cell lung cancer (SCLC) began\nenrolling patients in early 2026 and is currently enrolling patients across\nmultiple VA sites in the US.\n\nAbout the Drug Response Predictor – DRP(®) Companion Diagnostic\nAllarity uses its drug-specific DRP® to select those patients who, by the\ngene expression signature of their cancer, may have a high likelihood of\nbenefiting from a specific drug. By screening patients before treatment, and\nonly treating those patients with a sufficiently high, drug-specific DRP\nscore, the therapeutic benefit rate may be enhanced. The DRP method builds on\nthe comparison of sensitive vs. resistant human cancer cell lines, including\ntranscriptomic information from cell lines, combined with clinical tumor\nbiology filters and prior clinical trial outcomes. DRP is based on messenger\nRNA expression profiles from patient biopsies. The DRP® platform has shown an\nability to provide a statistically significant prediction of the clinical\noutcome from drug treatment in cancer patients across dozens of clinical\nstudies (both retrospective and prospective). The DRP platform, which may be\nuseful in all cancer types and is patented for dozens of anti-cancer drugs,\nhas been extensively published in the peer-reviewed literature.\n\n\n\nAbout Allarity Therapeutics\nAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage\nbiopharmaceutical company dedicated to developing personalized cancer\ntreatments. The Company is focused on development of stenoparib, a novel\nPARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP®\ntechnology to develop a companion diagnostic that can be used to select those\npatients expected to derive the greatest clinical benefit from stenoparib.\nAllarity’s principal operations are located in Denmark and its U.S. business\naddress is in Florida and is committed to addressing significant unmet medical\nneeds in cancer treatment. For more information, visit www.allarity.com.\n\nFollow Allarity on Social Media\nLinkedIn: https://www.linkedin.com/company/allaritytx/\n\nForward-Looking Statements \nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995.\nForward-looking statements provide the Company’s current expectations or\nforecasts of future events. The words “anticipates,” “believe,”\n“continue,” “could,” “estimate,” “expect,” “intends,”\n“may,” “might,” “plan,” “possible,” “potential,”\n“predicts,” “project,” “should,” “would” and similar\nexpressions may identify forward-looking statements, but the absence of these\nwords does not mean that a statement is not forward-looking. These\nforward-looking statements include, but are not limited to, statements\nregarding the term, scope, validity, enforceability and commercial value of\nthe Company’s newly granted U.S. patent covering its stenoparib-specific\nDRP® companion diagnostic, including the patent’s term extending into April\n2042; the ability of the patent to protect the use of the stenoparib DRP®\ntest to identify patients most likely to derive clinical benefit from\nstenoparib treatment; the anticipated contribution of the patent to the\nCompany’s intellectual property and commercial strategy; the potential\nutility and regulatory acceptance of the DRP® companion diagnostic strategy;\nand the Company’s plans and ability to advance stenoparib and its companion\ndiagnostic toward clinical development, regulatory approval and\ncommercialization. Any forward-looking statements in this press release are\nbased on management’s current expectations of future events and are subject\nto multiple risks and uncertainties that could cause actual results to differ\nmaterially and adversely from those set forth in or implied by such\nforward-looking statements. These risks and uncertainties include, but are not\nlimited to, risks related to the scope, validity, enforceability, maintenance\nand interpretation of the granted patent; the possibility of third-party\nchallenges, administrative proceedings, litigation or other actions affecting\nthe patent or the Company’s intellectual property rights; the possibility\nthat the actual patent term or scope of protection may differ from the\nCompany’s expectations; the Company’s ability to obtain, maintain and\nenforce intellectual property protection in the United States and other\njurisdictions; the potential utility, clinical validation and regulatory\nacceptance of the DRP® companion diagnostic strategy; the Company’s ability\nto conduct, enroll and complete its ongoing and future clinical trials; the\npossibility that prior clinical observations may not be confirmed in ongoing\nor future studies; the ability of stenoparib to demonstrate sufficient safety,\nefficacy, tolerability or clinical benefit to support further development or\nregulatory approval; and the Company’s ability to secure sufficient\nfinancial, operational, manufacturing and clinical resources to continue\ndevelopment of stenoparib. For a discussion of other risks and uncertainties,\nand other important factors, any of which could cause our actual results to\ndiffer from those contained in the forward-looking statements, see the section\nentitled “Risk Factors” in our Form 10-K annual report filed with the\nSecurities and Exchange Commission (the “SEC”) on March 30, 2026, and our\nQuarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with\nthe SEC on May 15, 2026, available at the SEC’s website at www.sec.gov, as\nwell as discussions of potential risks, uncertainties and other important\nfactors in the Company’s subsequent filings with the SEC. All information in\nthis press release is as of the date of the release, and the Company\nundertakes no duty to update this information unless required by law.\n\n###\n\nCompany Contact:         \n        investorrelations@allarity.com\n\n        \nMedia Contact:\n        Thomas Pedersen\n        Carrotize PR & Communications\n        +45 6062 9390\n        tsp@carrotize.com\n\nAttachment\n*     Allarity Therapeutics Announces the Grant of Essential U.S. Patent for\nStenoparib DRP\n(https://ml-eu.globenewswire.com/Resource/Download/8e101559-c669-4eed-860e-610f95e7150f)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7RPDb3","title":"Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic","author":"Globe Newswire","ticker":"ALLR","created":"2026-06-30T12:00:00.577Z","tickers":["ALLR"],"exchange":"NASDAQ","article_body":"* Key U.S. patent now protects exclusivity for developing stenoparib with the\nstenoparib-DRP(®) until April 2042\nTARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc.\n(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage\npharmaceutical company dedicated to developing stenoparib (2X-121)—a\ndifferentiated, dual PARP and WNT pathway inhibitor—today announced that the\nUnited States Patent and Trademark Office (USPTO) has granted the key U.S.\npatent covering its proprietary stenoparib-specific Drug Response Predictor\n(DRP®) companion diagnostic. The newly granted patent has a term extending\ninto April 2042. The patent grant follows the USPTO’s Notice of Allowance\nfor the stenoparib DRP® companion diagnostic formerly announced by Allarity\nin April 2026.\n\n“This is a critical step for Allarity. With this U.S. patent now granted and\nproviding protection into 2042, we have established an important long-term\nintellectual property foundation for stenoparib and our DRP® companion\ndiagnostic,” said Thomas Jensen, Chief Executive Officer of Allarity\nTherapeutics. “Looking ahead, our goal is to use the stenoparib DRP® to\nhelp identify the patients most likely to benefit from treatment. This patent\nprovides the foundation for advancing a more precise, patient-selection-driven\napproach to ovarian cancer and accelerating stenoparib toward FDA approval.”\n\nThe granted patent covers methods for predicting clinical benefit from\nstenoparib based on gene-expression profiles derived from tumor samples, as\nwell as methods for selecting patients most likely to benefit from stenoparib\ntreatment using the stenoparib DRP® test. The patent protects Allarity’s\nlong-term commercial strategy, allowing exclusivity for stenoparib when used\nin concert with the stenoparib DRP® companion diagnostic in the United States\ninto April 2042.\n\nAllarity has also secured patent protection for the stenoparib DRP® in Europe\nand Australia into 2039, with related applications pending in several\nadditional international markets.\n\nAbout Stenoparib/2X-121\nStenoparib is an orally available, small-molecule dual-targeted inhibitor of\nPARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant\nattention as emerging therapeutic targets for cancer, principally due to their\nrole in regulating the WNT signaling pathway. Aberrant WNT/β-catenin\nsignaling has been implicated in the development and progression of numerous\ncancers, especially drug-resistant cancers. By inhibiting PARP and blocking\nWNT pathway activation, stenoparib’s unique therapeutic action shows\npotential as a promising therapeutic for many cancer types, including ovarian\ncancer, small cell lung cancer and colorectal cancer. Allarity has secured\nexclusive global rights for the development and commercialization of\nstenoparib, which was originally developed by Eisai Co. Ltd. and was formerly\nknown under the names E7449 and 2X-121. Allarity has completed its first Phase\n2 trial for stenoparib in advanced ovarian cancer patients. That trial showed\npromising and durable clinical benefit in ovarian cancer patients who had 2+\nlines of therapy and were given stenoparib twice daily. The updated data from\nthis study were presented at the AACR special conference on advances in\novarian cancer in September 2025. Note that analyses may change as the study\nfully matures. A new protocol was designed expressly to capitalize on this\nemerging clinical experience with stenoparib in platinum resistant patients\nand began enrolling patients in the summer of 2025. This amended protocol\nenrolls only platinum resistant or platinum-ineligible patients and is\ndesigned to accelerate the clinical development of stenoparib toward FDA\napproval. In parallel, a separate Phase 2 trial evaluating stenoparib in\ncombination with temozolomide for relapsed small cell lung cancer (SCLC) began\nenrolling patients in early 2026 and is currently enrolling patients across\nmultiple VA sites in the US.\n\nAbout the Drug Response Predictor – DRP(®) Companion Diagnostic\nAllarity uses its drug-specific DRP® to select those patients who, by the\ngene expression signature of their cancer, may have a high likelihood of\nbenefiting from a specific drug. By screening patients before treatment, and\nonly treating those patients with a sufficiently high, drug-specific DRP\nscore, the therapeutic benefit rate may be enhanced. The DRP method builds on\nthe comparison of sensitive vs. resistant human cancer cell lines, including\ntranscriptomic information from cell lines, combined with clinical tumor\nbiology filters and prior clinical trial outcomes. DRP is based on messenger\nRNA expression profiles from patient biopsies. The DRP® platform has shown an\nability to provide a statistically significant prediction of the clinical\noutcome from drug treatment in cancer patients across dozens of clinical\nstudies (both retrospective and prospective). The DRP platform, which may be\nuseful in all cancer types and is patented for dozens of anti-cancer drugs,\nhas been extensively published in the peer-reviewed literature.\n\n\n\nAbout Allarity Therapeutics\nAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage\nbiopharmaceutical company dedicated to developing personalized cancer\ntreatments. The Company is focused on development of stenoparib, a novel\nPARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP®\ntechnology to develop a companion diagnostic that can be used to select those\npatients expected to derive the greatest clinical benefit from stenoparib.\nAllarity’s principal operations are located in Denmark and its U.S. business\naddress is in Florida and is committed to addressing significant unmet medical\nneeds in cancer treatment. For more information, visit www.allarity.com.\n\nFollow Allarity on Social Media\nLinkedIn: https://www.linkedin.com/company/allaritytx/\n\nForward-Looking Statements \nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act of 1995.\nForward-looking statements provide the Company’s current expectations or\nforecasts of future events. The words “anticipates,” “believe,”\n“continue,” “could,” “estimate,” “expect,” “intends,”\n“may,” “might,” “plan,” “possible,” “potential,”\n“predicts,” “project,” “should,” “would” and similar\nexpressions may identify forward-looking statements, but the absence of these\nwords does not mean that a statement is not forward-looking. These\nforward-looking statements include, but are not limited to, statements\nregarding the term, scope, validity, enforceability and commercial value of\nthe Company’s newly granted U.S. patent covering its stenoparib-specific\nDRP® companion diagnostic, including the patent’s term extending into April\n2042; the ability of the patent to protect the use of the stenoparib DRP®\ntest to identify patients most likely to derive clinical benefit from\nstenoparib treatment; the anticipated contribution of the patent to the\nCompany’s intellectual property and commercial strategy; the potential\nutility and regulatory acceptance of the DRP® companion diagnostic strategy;\nand the Company’s plans and ability to advance stenoparib and its companion\ndiagnostic toward clinical development, regulatory approval and\ncommercialization. Any forward-looking statements in this press release are\nbased on management’s current expectations of future events and are subject\nto multiple risks and uncertainties that could cause actual results to differ\nmaterially and adversely from those set forth in or implied by such\nforward-looking statements. These risks and uncertainties include, but are not\nlimited to, risks related to the scope, validity, enforceability, maintenance\nand interpretation of the granted patent; the possibility of third-party\nchallenges, administrative proceedings, litigation or other actions affecting\nthe patent or the Company’s intellectual property rights; the possibility\nthat the actual patent term or scope of protection may differ from the\nCompany’s expectations; the Company’s ability to obtain, maintain and\nenforce intellectual property protection in the United States and other\njurisdictions; the potential utility, clinical validation and regulatory\nacceptance of the DRP® companion diagnostic strategy; the Company’s ability\nto conduct, enroll and complete its ongoing and future clinical trials; the\npossibility that prior clinical observations may not be confirmed in ongoing\nor future studies; the ability of stenoparib to demonstrate sufficient safety,\nefficacy, tolerability or clinical benefit to support further development or\nregulatory approval; and the Company’s ability to secure sufficient\nfinancial, operational, manufacturing and clinical resources to continue\ndevelopment of stenoparib. For a discussion of other risks and uncertainties,\nand other important factors, any of which could cause our actual results to\ndiffer from those contained in the forward-looking statements, see the section\nentitled “Risk Factors” in our Form 10-K annual report filed with the\nSecurities and Exchange Commission (the “SEC”) on March 30, 2026, and our\nQuarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with\nthe SEC on May 15, 2026, available at the SEC’s website at www.sec.gov, as\nwell as discussions of potential risks, uncertainties and other important\nfactors in the Company’s subsequent filings with the SEC. All information in\nthis press release is as of the date of the release, and the Company\nundertakes no duty to update this information unless required by law.\n\n###\n\nCompany Contact:         \n        investorrelations@allarity.com\n\n        \nMedia Contact:\n        Thomas Pedersen\n        Carrotize PR & Communications\n        +45 6062 9390\n        tsp@carrotize.com\n\nAttachment\n*     Allarity Therapeutics Announces the Grant of Essential U.S. Patent for\nStenoparib DRP\n(https://ml-eu.globenewswire.com/Resource/Download/8e101559-c669-4eed-860e-610f95e7150f)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-30T12:00:00.65436711Z","server_sent_at_ms":1782820800654},"received_at":"2026-06-30T12:00:00.705Z","source_url":"https://www.globenewswire.com/news-release/2026/06/30/3319620/0/en/Allarity-Therapeutics-Announces-the-Grant-of-Essential-U-S-Patent-for-Its-Stenoparib-DRP-Companion-Diagnostic.html"},"analysis":{"id":"65730","press_release_id":"76460","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Allarity Therapeutics secured a key U.S. patent for its stenoparib DRP companion diagnostic, extending IP protection through April 2042.\n\nThe patent covers methods for predicting clinical benefit and selecting patients based on gene-expression profiles for the lead drug stenoparib.\n\nManagement views this as a critical step in establishing a long-term foundation for its precision oncology strategy, which currently includes Phase 2 trials in ovarian and small cell lung cancers.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Patent grant extends stenoparib IP protection to 2042, solidifying the companion diagnostic strategy."},"keyFigures":{"drugName":"stenoparib (2X-121)","phaseOfTrial":"Phase 2","customDimensions":{"patent_expiration_us":"April 2042","patent_expiration_intl":"2039"}},"quotedText":"This is a critical step for Allarity. With this U.S. patent now granted and providing protection into 2042, we have established an important long-term intellectual property foundation for stenoparib and our DRP® companion diagnostic","namedEntities":{"people":[{"name":"Thomas Jensen","role":"Chief Executive Officer"}],"products":["stenoparib","2X-121","stenoparib DRP® companion diagnostic"],"companies":[{"name":"Allarity Therapeutics, Inc.","ticker":"ALLR"},{"name":"Eisai Co. Ltd.","relationship":"original developer"},{"name":"United States Patent and Trademark Office","relationship":"regulatory body"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Grant of a key U.S. patent extending exclusivity for the lead asset's companion diagnostic to 2042 secures long-term IP protection, though the asset remains in Phase 2 development."},"tickerRelevance":{"others":[],"primary":"ALLR"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"ip-milestone","sectorWeight":"biotech"}},"event_type":"operations_update","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":3,"narrative":"Allarity Therapeutics secured a key U.S. patent for its stenoparib DRP companion diagnostic, extending IP protection through April 2042.\n\nThe patent covers methods for predicting clinical benefit and selecting patients based on gene-expression profiles for the lead drug stenoparib.\n\nManagement views this as a critical step in establishing a long-term foundation for its precision oncology strategy, which currently includes Phase 2 trials in ovarian and small cell lung cancers.","key_figures":{"drugName":"stenoparib (2X-121)","phaseOfTrial":"Phase 2","customDimensions":{"patent_expiration_us":"April 2042","patent_expiration_intl":"2039"}},"named_entities":{"people":[{"name":"Thomas Jensen","role":"Chief Executive Officer"}],"products":["stenoparib","2X-121","stenoparib DRP® companion diagnostic"],"companies":[{"name":"Allarity Therapeutics, Inc.","ticker":"ALLR"},{"name":"Eisai Co. Ltd.","relationship":"original developer"},{"name":"United States Patent and Trademark Office","relationship":"regulatory body"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-30T12:09:39.335Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"ip-milestone","sectorWeight":"biotech"}},"durationMs":131158,"modelName":"george-droid-qwen-72b"}}